Effects of the Oral Direct Thrombin Inhibitor Ximelagatran on P-Selectin Expression and Thrombin Generation in Atrial Fibrillation | Zendy

Michael Wolzt | Zendy; Stig Boström | Zendy; Mia Svensson | Zendy; Karin Wåhlander | Zendy; Margaretha Grind | Zendy; Troy C. Sarich | Zendy

Open Access

Effects of the Oral Direct Thrombin Inhibitor Ximelagatran on P-Selectin Expression and Thrombin Generation in Atrial Fibrillation

Author(s) -

Michael Wolzt,

Stig Boström,

Mia Svensson,

Karin Wåhlander,

Margaretha Grind,

Troy C. Sarich

Publication year - 2003

Publication title -

pathophysiology of haemostasis and thrombosis

Language(s) - English

Resource type - Journals

eISSN - 1424-8840

pISSN - 1424-8832

DOI - 10.1159/000073849

Subject(s) - ximelagatran , thrombin , atrial fibrillation , direct thrombin inhibitor , discovery and development of direct thrombin inhibitors , medicine , platelet , pharmacology , warfarin , dabigatran

This study investigated the pharmacodynamic effects of the oral direct thrombin inhibitor ximelagatran on platelet activation and thrombin generation in patients with nonvalvular atrial fibrillation. Using an open, group-matched study design, the effects of ximelagatran (36 mg twice daily for 5 days) were studied in 12 patients with permanent nonvalvular atrial fibrillation and in 12 healthy controls. After ximelagatran for 5 days, elevated platelet P-selectin expression in atrial fibrillation patients was lowered to that during coumarin treatment or in controls but had no effect in control subjects. Using the endogenous thrombin potential as a marker, ximelagatran decreased and delayed thrombin generation in both groups. In conclusion, direct thrombin inhibition with ximelagatran reduced elevated platelet P-selectin expression and inhibited thrombin generation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research